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Abstract: DO-HEALTH is a multi-center clinical trial among 2157 community-dwelling European men
and women age 70 and older. The 2x2x2 randomized-control factorial design trial tested the individual
and additive benefit, as well as the cost-effectiveness, of 3 interventions: vitamin D 2000 IU/day, omega-3
fatty acids 1000 mg/day (EPA + DHA, ratio 1:2), and a 30-minute 3 times/week home exercise (strength
versus flexibility). Each treatment tested has shown considerable prior promise from mechanistic studies,
small clinical trials, or large cohort studies, in the prevention of common age-related chronic diseases, but
definitive data are missing. DO-HEALTH will test these interventions in relation to 6 primary endpoints
(systolic and diastolic blood pressure, non-vertebral fractures, Short Physical Performance Battery score,
the Montreal Cognitive Assessment, and risk of infections), plus several secondary endpoints explored
in ancillary studies (i.e. rate of any falls and injurious falls, joint pain, oral health, quality of life, and
incident frailty). As the 3 interventions have distinct mechanisms of action for each of the 6 primary
endpoints, a maximum benefit is expected for their additive benefit as a “multi-modal” intervention.
The trial duration is 3 years with in-person contacts with all participants at 4 clinical visits and by
quarterly phone calls. Baseline and follow-up blood samples were collected in all participants to measure
changes in 25-hydroxyvitamin D and poly-unsaturated fatty acid concentrations. Our objective was to
test interventions that are expected to promote healthy aging and longer life expectancy and that can be
easily and safely implemented by older community-dwelling adults.
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A B S T R A C T   
DO-HEALTH is a multi-center clinical trial among 2157 community-dwelling European men and women age 70 
and older. The 2x2x2 randomized-control factorial design trial tested the individual and additive benefit, as well 
as the cost-effectiveness, of 3 interventions: vitamin D 2000 IU/day, omega-3 fatty acids 1000 mg/day 
(EPA + DHA, ratio 1:2), and a 30-minute 3 times/week home exercise (strength versus flexibility). Each 
treatment tested has shown considerable prior promise from mechanistic studies, small clinical trials, or large 
cohort studies, in the prevention of common age-related chronic diseases, but definitive data are missing. DO- 
HEALTH will test these interventions in relation to 6 primary endpoints (systolic and diastolic blood pressure, 
non-vertebral fractures, Short Physical Performance Battery score, the Montreal Cognitive Assessment, and risk 
of infections), plus several secondary endpoints explored in ancillary studies (i.e. rate of any falls and injurious 
falls, joint pain, oral health, quality of life, and incident frailty). As the 3 interventions have distinct mechanisms 
of action for each of the 6 primary endpoints, a maximum benefit is expected for their additive benefit as a 
“multi-modal” intervention. The trial duration is 3 years with in-person contacts with all participants at 4 clinical 
visits and by quarterly phone calls. Baseline and follow-up blood samples were collected in all participants to 
measure changes in 25-hydroxyvitamin D and poly-unsaturated fatty acid concentrations. Our objective was to 
test interventions that are expected to promote healthy aging and longer life expectancy and that can be easily 
and safely implemented by older community-dwelling adults.   
https://doi.org/10.1016/j.cct.2020.106124 
Received 13 March 2020; Received in revised form 11 August 2020; Accepted 18 August 2020    
⁎ Corresponding author at: Dept. of Geriatric Medicine and Aging Research, University Hospital Zurich, RAE B, Rämistrasse 100, CH-8091 Zurich, Switzerland. 
E-mail address: Heike.Bischoff@usz.ch (H.A. Bischoff-Ferrari). 
1 In Memory of Dieter Felsenberg, a passionate scientist in clinical muscle and bone research. 
2 DO-HEALTH Research Group is listed in the Appendix 1. 
Contemporary Clinical Trials 100 (2021) 106124
Available online 26 August 20201551-7144/ © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
1. Introduction 
In Europe, the number of adults age 65 years and older is expected to 
be more than double in the coming 40 years. Specifically, for the five DO- 
HEALTH countries, the UN Population Division estimated in 2019 that the 
population age 65 and older will grow by 78% in Switzerland, 61% in 
Austria, 32% in Germany, and 41% in France between 2020 and 2060 [1]. 
Concomitantly the number of older adults with age-related chronic dis-
eases is increasing [2,3]. Thus, therapeutic interventions that are effective, 
affordable, and well-tolerated in the prevention of chronic conditions at 
older ages are urgently needed and have the potential for major impact on 
public health. Among the most promising interventions that meet these 
requirements are vitamin D, marine omega-3 fatty acids (n-3 s), and 
physical exercise. However, their individual and combined effects in older 
adults have yet to be confirmed in a large clinical trial [4–6]. 
About half of older adults worldwide have low vitamin D levels 
(< 50 nnmol/mL or  <  20 ng/mL) [7]. This is in part explained by their 
skin being less able to synthesize vitamin D in response to solar radiation, 
less sun exposure due to sedentary life style, and to sun avoidance in 
older adults [8–12]. Also, dietary sources of vitamin D are rare and 
largely limited to fatty fish, fish liver oil, egg yolk, and mushrooms 
[119]. Similarly, low n-3 s intake and lack of exercise are acknowledged 
public health concerns, especially in the older adult population [2,3,13]. 
However, despite the recognition of frequent inadequacy of vitamin D, n- 
3 s, and exercise, broad public recommendations cannot currently be 
justified because definitive data on health benefits and risks of the 3 
interventions individually and in combination are lacking. 
Meta-analyses of randomized clinical trials (RCTs) have reported pro-
tective effects of n-3 s against cardiovascular disease [14], cognitive decline 
[15,16], and bone turnover markers [17]. However, several meta-analyses 
found no significant associations with coronary heart disease [18,19] and 
cognitive function [20,21]. Vitamin D has also been associated with in-
consistent findings for all-cause all causes of mortality [22–24], fractures 
(particularly when combined with calcium) [25–27], and respiratory 
infections [28,29] in meta-analysis of RCTs. Physical exercise has been as-
sociated with reduced risk of community-acquired pneumonia [30] and 
cognitive decline [31], improvement in blood pressure [32] and functional 
performance [33]. However, evidence of the benefits of physical exercise on 
risk of fractures is lacking from randomized controlled trials. 
DO-HEALTH was designed to establish evidence for the role of vitamin 
D, n-3 s, and a simple home based strength exercise program (SHEP), both 
individually and as a combined intervention, in chronic conditions pre-
vention at older ages, for 6 primary endpoints (systolic and diastolic blood 
pressure change, non-vertebral fractures, the Short Physical Performance 
Battery (SPPB) [34], the Montreal Cognitive Assessment (MoCA) [35], and 
infections), addressing 5 health domains (cardiovascular health, bone 
health, muscle health, brain-health, and immunity), supported and ex-
tended by a series of secondary and exploratory endpoints. 
2. Methods 
2.1. Study design and hypothesis 
DO-HEALTH is a 3-year randomized, double-blind, placebo-con-
trolled, 2x2x2 factorial design trial that tested 3 primary treatments:  
(1) Dietary supplement of 2000 IU vitamin D per day compared to 
placebo  
(2) Dietary supplement of 1 g of n-3 s (eicosapentaenoic acid 
(EPA) + docosahexaenoic acid (DHA), ratio 1:2, from marine 
algae) compared to placebo.  
(3) SHEP (Strength) of 30 min 3 times a week compared to a control 
exercise program (Flexibility) 30 min 3 times a week. 
Our hypotheses are that vitamin D, n-3 s, and SHEP, alone or in 
combination, can improve six primary endpoints: reduction in systolic 
and diastolic blood pressure (cardiovascular health), reduction in non- 





















































Fig. 1. DO-HEALTH study schema. 
Legend: Participants were randomized in 8 arms and followed over 3 years (36 months) in 4 clinical visits (Baseline, 12-month, 24-month, 36-month visits) and in 9 
three-monthly phone calls (3-, 6-, 9-, 15-, 18-, 21-, 27-, 30-, 33-month phone calls). 
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health), increase in MoCA scores (brain-health), and reduction in in-
fection rates (immunity). Therefore, all analyses will test the effect of 
each strategy individually and their combinations (Fig. 1). The factorial 
design was chosen to increase power by taking advantage of our as-
sumption that vitamin D, n-3 s, and the SHEP have distinct mechanisms 
of action and therefore may have an additive effect on the study end-
points. If the analyses show that the effects are not additive, then all 
effects can still be estimated without bias, but with reduced power. 
The trial was performed at 7 recruitment centers located in 5 
European countries: Switzerland (University of Zurich, Basel University 
Hospital, Geneva University Hospital), France (University of Toulouse 
Hospital Center), Germany (Charité Berlin), Portugal (University of 
Coimbra), and Austria (Innsbruck Medical University). 
2.2. Endpoints 
Fig. 2 lists the schedule of assessment of the 6 DO-HEALTH primary 
endpoints (Fig. 2A), and all secondary endpoints (Fig. 2B), as well as 
health-care utilization data collected at each time point. Supplementary 
Table 1 describes all endpoints assessed in DO-HEALTH (primary, sec-
ondary, exploratory, and biomarkers). Supplementary Table 2 describes all 
questionnaires used in DO-HEALTH at baseline, 12, 24 and 36 months of 
follow-up. 
2.3. Primary endpoints assessments 
The DO-HEALTH trial addressed 6 primary endpoints in 5 domains 
(Fig. 2): 
2.3.1. Cardiovascular 
Systolic and diastolic blood pressure changes were assessed by blood 
pressure measurements after 5-min rest in a seated position following a 
standardized protocol validated in a DO-HEALTH pilot trial [37]. 
2.3.2. Bone 
Incidence of non-vertebral fractures. All fracture events were con-
firmed by X-ray reports or medical records that describe an X-ray report 
of the fracture or mention the repair of the fracture. 
2.3.3. Muscle 
Functional decline was assessed with the Short Physical 
Performance Battery (SPPB) [34], which is an objective assessment tool 
for evaluating lower extremity function in older persons. It was devel-
oped by the National Institute on Aging and has been validated ex-
tensively in epidemiologic studies and in intervention trials [34]. The 
SPPB is a brief performance-based test that includes walking speed, 
repeated chair stands, and a balance test. Its three components are 
scored between 0 and 4, with 4 indicating the highest level of perfor-
mance, and are summed up to yield an overall score. 
2.3.4. Brain 
Cognitive decline was assessed using the Montreal Cognitive 
Assessment (MoCA) [35]. The MoCA is more structured and covers 
more cognitive domains than the Mini Mental State Examination 
(MMSE) and has been found to be more sensitive than MMSE with re-
spect to mild cognitive impairment [35,38–41]. 
2.3.5. Immunity 
Rate of any infection. Upon each contact, the participant was asked 
whether any infection with or without fever had occurred and whether 
and when a vaccination was performed (i.e. flu vaccination). When a 
participant experienced an infection, a detailed infection questionnaire 
36 months
Visit 4










Systolic blood pressure change
Functional decline (assessed by Short Physical 
Performance Test Battery)
Incidence of non-vertebral fractures (confirmed 
by X-ray or medical reports)
Cognitive decline (assessed by Montreal 
Cognitive Assessment) 
Rate of any infection (questionnaire)








Diastolic blood pressure change
Fig. 2. Schedule of assessment of the primary (A) and secondary (B) endpoints. 
Legend: In DO-HEALTH, participants were followed over 3 years (36 months). After the prescreening phone call, participants had 4 clinical visits, including baseline, 
and 9 phone calls. 
*assessments performed with 1502 participants, 4 recruiting centers equipped with Lunar iDXA, GE Healthcare machines (Berlin, Coimbra, Toulouse, and 
Zurich).**Dual tasking gait variability was assessed in 250 participants at baseline, 12, 24, and 36 months by gait analyses and dual task assessments (GAITRite® 
Platinum, CIR Systems, PA, USA) in one recruitment center (Basel University Hospital). Participants performed 4 walking tasks with and without cognitive challenge 
[36]. ¶Quality of life was evaluated at baseline, and every 6 months afterwards (during 6-, 18-, 30-month phone calls, and at 12-, 24-, and 36-month clinical visits). 
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developed in two pilot trials to DO-HEALTH [42,43] was administered. 
The questionnaire elicits information about symptoms, treatment, pri-
mary doctor contact and medical assessments. Every case of infection 
was verified by an independent physician using all available informa-
tion (symptoms, treatment, and medical records). 
2.4. Secondary endpoints assessments 
DO-HEALTH also assessed additional secondary endpoints that 














Visit 0 month 15, 18, and 21 month 27, 30, and 33
Incidence of hip, vertebral, and total fractures
Rate of falling (rate of any low trauma, injurious 
falls, number of participants who fell with and 
without injury)
Reaction time and grip strength
Muscle mass (upper and lower extremities)*
SECONDARY ENDPOINTS
Musculoskeletal pain




Risk of incident hypertension 
Mental health decline and incidence of depression 
Rates of any upper respiratory infection, incident 
flu-like illness, incident severe infections that lead 




Dual tasking gait variability** 
Dual tasking 10 meters gait speed
Severity of knee pain in participants with 
symptomatic knee osteoarthritis
Cartilage
Rate of knee buckling
NSAID use and number of joints with pain
Decline in oral health and tooth loss
Dental
Rate of Gastrointestinal symptoms
Gastrointestinal
Fasting blood concnetration of glucose and
insulin
Glucose-metabolic
Body composition and fat mass with DXA 
measurements*




Incident frailty and disability
Incident nursing home admision, rate of acute
hospital admissions and mortality
(B)
Fig. 2.  (continued)  
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2.4.1. Cardiovascular  
▪ Risk of incident hypertension. Among participants without a diag-
nosis of hypertension, the first occurrence of SBP ≥140 mmHg or 
DBP ≥90 mmHg on a study visit qualified as incident hypertension. 
In addition, a chart-based diagnosis of incident hypertension and/or 
a report of new use of an anti-hypertensive drug qualified as in-
cident hypertension. 
2.4.2. Bone   
▪ Incidence of hip fractures. Diagnosis of a hip fracture was confirmed 
by X-ray report or medical record mentioning an X-ray report or 
fracture repair. Hip fractures included femoral neck and trochan-
teric fractures.  
▪ Incidence of vertebral fractures (vertebral morphometry). Diagnosis 
of a vertebral fracture was based on iDXA vertebral morphometry 
assessment among 1492 participants at the four recruiting centers 
equipped with Lunar iDXA, GE Healthcare machines (Zurich, Berlin, 
Toulouse, Coimbra). All vertebral bodies of the thoracic and the 
lumbar spine were categorized as normal or deformed. Deformities 
were classified as: mild (grade 1, 20–25% reduction in either ante-
rior or middle height relative to posterior height of the same ver-
tebral body, or reduction of posterior height relative to posterior 
height of adjacent vertebral bodies); moderate (grade 2, 26–40% 
reduction in any height); and severe (grade 3, > 40% reduction in 
any height) deformities. All vertebral deformities were classified 
according to etiology (for example osteoporotic, traumatic, degen-
erative, etc.). The assessment of prevalent and incident vertebral 
deformities based on iDXA morphometry was blinded to treatment 
and performed at one specialized center (Berlin). Additionally, we 
assessed the incidence of mild to severe vertebral deformities (e.g. 
biconcave, compression, and wedge), and the incidence of moderate 
to severe vertebral deformities due to osteoporosis.  
▪ Incidence of total fractures. Sum of any new non-vertebral and any 
new vertebral fracture (mild to severe deformity) based on vertebral 
morphometry assessment in the subset of 1492 participants at the 
four recruiting centers equipped with Lunar iDXA, GE Healthcare 
machines (Zurich, Berlin, Toulouse, Coimbra). Bone mineral density 
at the spine and hip based on iDXA measurements was assessed in 
1492 participants at four recruiting centers equipped with Lunar 
iDXA, GE Healthcare machines. The measurements were performed 
during each clinical visit. Both (right and left) proximal femurs were 
scanned at baseline. At follow-up, only the hip on the side that had 
the lower bone mineral density value of the total femur (hip) at 
baseline was measured. If the hip side with the lower baseline bone 
mineral density became unsuitable for DXA measurement (e.g. due 
to fracture or endoprosthesis during the course of the study), the 
other side was analyzed. 
2.4.3. Muscle   
▪ Rate of falling (rate of any low trauma-, injurious falls, number of 
participants who fell with and without injury). Falling was defined 
as unintentionally coming to rest on the ground, floor, or other 
lower level (coming to rest against furniture or a wall is not con-
sidered a fall). Incident falls were ascertained with a questionnaire 
to assess the circumstance of each fall and associated injuries.  
▪ Reaction time and grip strength. Reaction time was assessed with 
repeated chair stands (5 repeats as part of the SPPB [34]), and 
muscle strength was assessed with a validated grip strength protocol 
using Martin vigorimeter [44]. 
▪ Muscle mass in the upper and lower extremities. Muscle mass (ap-
pendicular lean mass/height2) was measured by iDXA in 1492 par-
ticipants at the four recruiting centers equipped with Lunar iDXA, GE 
Healthcare machines (Berlin, Coimbra, Toulouse, and Zurich).  
▪ Musculoskeletal pain was assessed using McGill pain map [45].  
▪ Dual tasking 10 m gait speed was assessed by comparing normal gait 
speed against gait speed if combined with a simple cognitive task 
over a distance of 10 m. Gait speed was measured with a stop watch 
under two conditions: “single task,” usual walking at preferred 
speed and using usual walking aid, and “dual task”, walking while 
subtracting serial twos from a predefined number (baseline: from 
50; 12 months: from 100; 24 months: from 70; 36 months: from 80) 
under the same conditions– without explicit instructions regarding 
prioritization (walking or counting) [46]. The difference between 
the two times was evaluated for this endpoint. At the study center in 
Basel, dual tasking gait speed was measured using the GAITRite 
electronic walkway system in addition. 
2.4.4. Brain   
▪ Mental health decline and incidence of depression were assessed 
using an excerpt from the Geriatric Depression Scale (GDS) [47,48].  
▪ Dual tasking gait variability was assessed in 250 participants by gait 
analyses and dual task assessments (GAITRite® Platinum, CIR 
Systems, PA, USA) in one recruitment center (Basel University 
Hospital). Participants performed 4 walking tasks with and without 
cognitive challenge [36]. 
2.4.5. Immunity   
▪ Rates of any upper respiratory infection, incident flu-like illness, 
incident severe infections that lead to hospital admission. This was 
based on an infection protocol (see primary endpoint). Infections 
and type of infection that lead to hospital admission were confirmed 
by medical records. 
2.4.6. Cartilage 
All participants were evaluated for prevalent knee osteoarthritis 
(OA) at baseline according to the modified American College of 
Rheumatology (ACR) criteria [49]. According to the modified ACR 
clinical criteria, prevalent and incident symptomatic knee OA were 
diagnosed in participants who reported knee pain on most days of the 
preceding week plus at least 3 of 6 criteria:  
1) Crepitus based on physical exam performed by the study medical 
doctor  
2) Age 50+  
3) Morning stiffness < 30 min  
4) Bony tenderness based on physical exam performed by the study 
medical doctor  
5) Bony enlargement based on physical exam performed by the study 
medical doctor  
6) Palpable warmth based on physical exam performed by the study 
medical doctor 
The ACR criteria for knee OA were modified for DO-HEALTH. The 
bony enlargement criterion was excluded due to its poor reproduci-
bility.  
▪ Severity of knee pain was assessed with the Knee injury and 
Osteoarthritis Outcome Score (KOOS [50]). 
▪ Rate of knee buckling was assessed with a comprehensive and va-
lidated questionnaire [51].  
▪ Nonsteroidal anti-inflammatory drugs (NSAID) use to control knee 
pain was assessed in all participants by standardized questionnaire. 
Additionally, participants were asked to report the average number 
of days per month they took NSAIDs.  
▪ Number of joints with pain was assessed in all participants with a 
joint map. 
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2.4.7. Dental   
▪ Decline in oral health was assessed with the Geriatric Oral Health 
Assessment Index (GOHAI [52]) questionnaire.  
▪ Tooth loss was assessed by tooth count by the study medical doctor 
including all teeth (own and all) and was validated with tooth prints 
at one recruitment center (University of Zurich). 
2.4.8. Gastro-intestinal   
▪ Gastro-intestinal symptoms were assessed using Rome III diagnostic 
questionnaire for the adult functional gastro-intestinal disorders [53]. 
2.4.9. Glucose-metabolic  
▪ Fasting blood concentration of glucose and insulin. Insulin sensi-
tivity and beta cell function derived from indices of fasting glucose 
and insulin concentrations were calculated using quantitative in-
sulin-sensitivity check index (QUICKI), and the HOMA index [54].  
▪ Body composition and fat mass were measured by iDXA in 1502 
participants recruited by four centers equipped with Lunar iDXA, GE 
Healthcare machines. We assessed trunk and upper and lower ex-
tremity fat mass. 
2.4.10. Kidney   
▪ Decline in kidney function was measured by blood creatinine levels 
and estimated glomerular filtration rate with the Cockcroft-Gault 
formula [55]. 
2.4.11. Global health   
▪ Quality of life was evaluated using the EQ5D-3 L questionnaire.  
▪ Incident frailty was assessed with the Survey of Health, Aging and 
Retirement in Europe Frailty Instrument (SHARE-FI) [56]. SHARE-FI 
closely resembles the traditional Fried's variables [57,58], and defines 
frailty condition by evaluating exhaustion, weight loss, slowness, low 
activity and weakness (the latter assessed by measuring handgrip 
strength).  
▪ Incident disability regarding activities of daily living was measured 
by the PROMIS-HAQ [59]. We assessed the risk of at least one new 
limitation in 20 activities of daily living (we assessed having at least 
some difficulty to do the activity / unable to do the activity).  
▪ Incident nursing home admissions, rate of acute hospital admissions 
and mortality were assessed every 3 months. Mortality was con-
firmed by medical record or death certificate; cause of death was 
established from medical records or death certificate and classified 
as follows: cardiovascular, cancer, severe infections, or other. 
2.5. Diet assessment for subgroup analyses (calcium/protein intake) 
We developed the electronic DO-HEALTH Food Frequency 
Questionnaire (FFQ) targeted at older adults. The instrument was cre-
ated to be consistent across the DO-HEALTH countries and the DO- 
HEALTH study languages (German, French, and Portuguese). The FFQ 
structure is based on food groups (the so-called European Food Groups, 
EFGs). This feature makes the tool easily used in culturally different 
populations, as compared to FFQs organized e.g. by meal patterns. Each 
food group includes several distinct food items. For each item the fre-
quency of consumption, in terms of a standard portion, is assessed: 
rarely/never; 1–3 per month; 1 per week; 2–4 per week; 5–6 per week; 
1 per day; 2–3 per day; 4–5 per day; 6+ per day. Additionally, for each 
fruit or vegetable item, we allow subjects to indicate if the consumption 
is only in season. Diet assessment by FFQ was performed at baseline and 
year 3. 
2.6. Economic model 
DO-HEALTH will assess the cost-benefit of the 3 interventions in a 
health economic model based on documented health care utilization. 
Health care utilization (direct medical and non-medical costs) was as-
sessed in 3-month intervals (4 clinical visits and 9 follow-up phone 
calls) with a standardized questionnaire in all 2157 participants. The 
economic model will be a decision-analytic model along the trial based 
on original participant-level data from the DO-HEALTH. The overall 
goal is to evaluate (quality-adjusted) life years, costs and incremental 
cost effectiveness of vitamin D supplementation, n-3 s supplementation, 
and the SHEP in order to support healthy aging to increase healthy life 
expectancy. The six primary endpoints and number of falls (secondary 
endpoint) will be considered, and we will extract country-specific, of-
ficially reported aggregate cost data to impute overall healthcare costs 
by participant. 
2.7. Direct data entry 
DO-HEALTH developed a system that allowed participants them-
selves to directly enter much of the data. Running on standard com-
puter tablets, questionnaires were presented using large, clear text and 
controls, with a simple and intuitive interface that received good re-
views from the participants. The software gave immediate feedback on 
missing or inconsistent data, so that these issues could be corrected 
immediately, before the participants moved on. The same forms were 
available in all of the DO-HEALTH languages. Since WLAN access 
throughout the study centers was not guaranteed, data was stored lo-
cally on the tablets until the end of the day, at which point it was up-
loaded to the central server. The tablets were part of the overall soft-
ware system which also allowed study staff to use PCs to enter data, 
check and resolve queries, randomize participants, schedule visits, al-
locate supplies, and check on the status of the study. 
2.8. Study interventions 
2.8.1. Vitamin D3 
Each active vitamin D capsule contained 1000 IU of Vitamin D3, an 
oily liquid consisting of crystalline Vitamin D3 (cholecalciferol) in 
medium chain triglycerides, stabilized with dl-α-tocopherol (vitamin E, 
2.5 promille). As placebo, participants received capsules with (high 
oleic sunflower oil). High oleic sunflower oil was cold pressed from 
organic sunflower kernels, refined and deodorized. The appearance was 
clear, light yellow and liquid. Each participant took two capsules daily 
for a total dose of 2000 IU vitamin D/day or placebo. 
2.8.2. Dose justification 
The dose of 2000 IU vitamin D/day is in accordance with data from 
prior studies suggesting that 2000 IU of vitamin D is the required dose 
to reach an average of 75 nmol/L of 25(OH)D previously suggested to 
be most desirable for fracture prevention [60–62]. In a prior study 
among hip fracture patients [63], 2000 IU vitamin D compared to 
800 IU vitamin D/day reduced hospital readmission by 39%, fall-re-
lated injury by 60%, and severe infections by 90%. Further, 2000 IU 
vitamin D raised 25(OH)D levels to at least 75 nmol/L in over 90% of 
participants at 6 and 12 month follow-up, and was safe as demonstrated 
by repeated serum and urinary calcium excretion assessments [63]. 
Notably, we chose a daily administration of vitamin D in DO-HEALTH, 
as unphysiologically high intermittent bolus doses of vitamin D may be 
ineffective or have detrimental effects on falls [64,65] and fractures 
[66,67]. Similar to the U.S. Vital trial [68], we chose vitamin D3 rather 
than D2 in DO-HEALTH because vitamin D3 is associated with higher 
increase in serum 25(OH)D concentrations and decreased mortality in 
older adults [22,69,70]. 
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2.8.3. Safety 
The safety of 2000 IU/day of vitamin D is further supported by our 
benefit-risk analysis wherein a safe upper intake level of 10,000 IU of 
vitamin D/day was estimated [62]. As all DO-HEALTH participants, 
according to current guidelines [71], were allowed to have an addi-
tional vitamin D intake of 800 IU/day, the maximum total intake of 
vitamin D was 2800 IU/day in the treatment group and 800 IU/day in 
the control group. These intakes are below the safe upper level of 
4000 IU/day as defined by the Institute of Medicine [72]. 
2.8.4. We have not included calcium supplementation as a component of the 
intervention 
At the higher dose of vitamin D intake, additional high dose calcium 
supplementation (≥ 1000 mg), either alone or in combination with vitamin 
D, was not beneficial for fracture reduction [25,73]. However, since DO- 
HEALTH was designed, new evidence has emerged that the combination of 
calcium and vitamin D may be more effective at the skeleton than vitamin D 
alone [27]. In the participant instructions, we encouraged participants to 
meet calcium needs from dietary sources. A personal intake of calcium 
supplements up to 500 mg daily was allowed in DO-HEALTH. 
2.9. Omega-3 fatty acids (n-3s) 
Each active n-3 s capsule contained 500 mg of eicosapentaenoic acid 
(EPA) and docosahexanoic acid (DHA) in a ratio of 1:2. The formulation 
was an oily liquid containing at least 75% n-3 polyunsaturated fatty 
acids in the form of ethyl esters predominantly as EPA and DHA. It was 
stabilized with mixed tocopherols and ascorbyl palmitate. Rosemary 
extract was used as a processing aid. The placebo capsule contained a 
high oleic sunflower oil. Participants were instructed to take orally 2 
study capsules daily for a total dose was 1000 mg of EPA and DHA or 
placebo. To reduce the risk of fishy after taste (and therefore risk of 
unblinding), we took several precautions: 1) we used n-3 s from algae, 
2) all capsules had a gastric coating to be released only in the intestine, 
and 3) we instructed participants to take the capsules with dinner (or 
the preferred meal) and a cold drink (water or juice). 
2.9.1. Dose justification 
We chose 1 g of n-3 s daily as the treatment dose of n-3 s as this was 
beneficial in one secondary prevention trial for cardiovascular health 
[74]. Although the optimal ratio of EPA to DHA is unknown [75–77], 
we selected a 1:2 ratio of EPA to DHA. A total dose of 850 mg/day was 
used in the GISSI-Prevenzione Trial (EPA to DHA ratio, 1.2:1) [74] and 
AREDS (EPA to DHA ratio, 1.86:1), whilst a dose of 1.8 g/day of EPA 
was used in JELIS [78]. Ongoing trials are currently investigating 
higher doses n-3 s. VITAL tested a dose of 1 g/ day in a ratio of 1.3:1 of 
EPA to DHA [68], REDUCE-IT selected a dose of 4 g/day of icosapent 
ethyl, a highly purified ethyl ester of EPA [79], and STRENGTH, a dose 
of 1 g/day of n-3 s without specifying the ratio [80]. Given that the 
average intake of EPA + DHA is 100 to 350 mg/d in many parts of 
Europe [81,82], the proposed intervention of 1 g/day is expected to 
increase the average participant's n-3 s intake by a factor of 3 to 10. 
2.9.2. Safety 
Health risks associated with fish oil are minimal and marine n-3 s 
doses of up to 3 g daily are considered safe. Although n-3 s have po-
tential antithrombotic effects, systematic reviews of data from small, 
short-term trials suggest that n-3 s supplements do not increase the risk 
of clinically significant bleeding at doses less than 4 g daily, even in 
combination with anticoagulant interventions such as aspirin or war-
farin [83,84]. 
2.10. Capsules stability 
Quality control regarding stability testing was performed in detail 
by the manufacturer of the study capsules (DSM Nutritional Products) 
for each batch. Furthermore, the analytical services laboratory eval-
uated the stability of vitamin D3 and n-3 s over the course of 3 years at 
25 °C in the soft gel capsules. 
2.11. Simple home-based strength exercise program (SHEP) 
A motivational and animated video was developed to instruct both 
the main exercise intervention (SHEP) as well as the control program 
(flexibility) in DO-HEALTH. Participants who wanted to step up the 
intensity of the program were invited to repeat the whole program, thus 
increasing the training time. The flexibility exercise program was de-
signed to serve as a high-quality control expected to have no benefit on 
the endpoints tested in DO-HEALTH. In addition, paper versions of both 
programs were provided to participants. Both programs were demon-
strated once during the baseline visit by an “instruction physiothera-
pist” not involved in the outcome assessment of DO-HEALTH, who also 
explained how to use the video, and the additional paper version. The 
physiotherapist also instructed the participant on the training strategy, 
e.g. to reduce repetitions or take a 1-week break if there was pain with 
exercise, and to call the recruitment center in case of any problems 
related to the program. Participants were asked to perform the home 
exercise program for 30 min 3 times a week. 
2.11.1. Strength home-based exercise intervention program (SHEP) 
SHEP consisted of the following exercises:  
▪ Sit-to-stand (quadriceps strength training)  
▪ One-leg stance (hip muscle strength training plus balance training)  
▪ Pull Backs against elastic resistance (seated position) 
▪ External shoulder rotation against elastic resistance (seated posi-
tion)  
▪ Steps on stairs (standing position) 
2.11.2. Control exercise (flexibility exercise) program 
Control exercise (flexibility exercise) program consisted of the fol-
lowing exercises:  
▪ Hip and knee mobility (seated position)  
▪ Hip mobility (standing position)  
▪ Trunk and chest mobility (seated position)  
▪ Shoulder mobility (seated position)  
▪ Ankle mobility (standing position) 
2.11.3. Program justification 
SHEP was validated in the DO-HEALTH pilot trial [63] among 173 
older adults with hip fracture. Results of the trial suggest that the 
program is successful in reducing the rate of falling by 25% (95% CI 
-44% to −1%) and the rate of fracture by 56% (95% CI −82% to 9%; 
P = .08) in the first year after the fracture [63]. Participants (65 years 
and older) who performed the intervention at least once a week also 
had a significant improvement in lower extremity function (timed up- 
and-go) and reaction time (repeated chair stands) [63]. In DO-HEALTH, 
all participants were asked to develop a routine that allowed optimal 
adherence. This routine was documented by the study staff. Ad-
ditionally, all participants were given a personal diary to record their 
adherence to the study intervention and the exercise program. The 
diary was collected at each clinical visit; it will not constitute a direct 
source of information for adherence, but it might be used pro re nata for 
confirmation of participant reported events. 
2.11.4. Safety 
Both exercise programs (SHEP and flexibility) tested in DO-HEALTH 
have been developed especially for the older population and entail only 
minimal risks and burden for the participants [63]. Both programs have 
already been tested in clinical study and shown to be well tolerated by 
seniors [63]. A possible side effect of the SHEP could be sore muscles 
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after the first few training sessions. Since an experienced study nurse or 
movement scientist instructed the SHEP, the risk of other side effects is 
minimal. 
2.12. Trial eligibility: inclusion and exclusion criteria 
Inclusion and exclusion criteria are described in Table 1. Briefly, 
DO-HEALTH participants had to be ≥70 years, with a MMSE ≥ 24, 
living in the community, and sufficiently mobile to reach the study 
center. At the screening visit, participants were asked to take a placebo 
capsule to test whether they were able to swallow the study capsules. 
2.13. Washout period 
Volunteers meeting eligibility criteria except by taking 1000 IU or 
more of vitamin D per day in the 3 months prior to enrollment were 
subject to the following provisions:  
• Provision 1: An individual who consumed an average vitamin D 
dose between 1000 and 2000 IU vitamin D/day in the 3 months 
prior to enrollment, could be enrolled after a 3-month wash-out 
period in which the maximum daily intake of vitamin D was limited 
to 800 IU.  
• Provision 2: An individual who consumed an average vitamin D 
dose higher than 2000 IU/day in the 3 months prior to enrollment, 
could be enrolled after a 6-month wash-out period in which the 
maximum daily intake of vitamin D was limited to 800 IU. 
2.14. Recruitment and randomization 
2.14.1. Source of participants 
DO-HEALTH participants were recruited through mailing lists of 
retirement authorities, churches, and other community services, pos-
ters, flyers, public events, advertisement in newspapers and other 
media, public events and educational programs and health care. The 
advertisements contained a contact phone number for each specific 
recruitment site that potential participants were asked to call for further 
information (DO-HEALTH telephone hotline – established at each re-
cruitment site). 
2.14.2. Randomization 
Potentially eligible participants were randomized if serum calcium 
was below 2.6 mmol/L, creatinine clearance was above 15 mL/min 
(calculated according to the Cockcroft-Gault formula [85]), and the 
study medical doctor saw the participant and confirmed all inclusion 
and exclusion criteria. 
Participants were randomized into the trial during the baseline visit. 
Randomization was computer-based (DO-HEALTH randomization soft-
ware). Stratified block randomization was used (block size of 16 in-
dividuals). Willing and eligible participants were randomized to one of 
the eight treatment groups stratified by the study center, low trauma 
fall during previous 12 months prior to the randomization day (yes/no), 
age (70–84 and 85+), and sex. Within each group, treatment assign-
ments were generated in blocks of sixteen individuals, with two in-
dividuals in each of the eight treatment combinations. Each study 
center was forced to keep a minimum balance between participants 
without falls and participants with at least one fall in the last year prior 
to enrollment, with at least 40% of fallers. The centers were also re-
quired to monitor balance in the age and sex strata. 
2.15. Blinding: study interventions and blood samples 
2.15.1. Study capsules and exercise kits 
Study capsules and exercise kits were blinded by a central 
Table 1 
Inclusion/exclusion criteria.    
Inclusion criteria Exclusion criteria    
1. Age ≥ 70 years  
2. MMSE ≥24  
3. Living in the community  
4. Sufficiently mobile to reach the study center  
5. Able to walk 10 m with or without a walking aid and getting in and out of a chair 
without help  
6. Able to swallow study capsules  
7. Able and willing to participate, sign informed consent (including consent to 
analyze all samples until drop-out or withdrawal) and cooperate with study 
procedures   
1. Consumption of more than 1000 IU vitamin D/day in the 3 months prior to enrollment, 
or unwillingness to limit vitamin D intake to the current standard of 800 IU/day of 
vitamin D during the course of the trial (see washout period).  
2. Unwillingness to limit calcium supplement dose to 500 mg/day for the duration of the 
trial  
3. Taking n-3 s supplements in the 3 months prior to recruitment and or unwilling to refrain 
from use of n-3 s supplements for the duration of the trial  
4. Use of any active vitamin D metabolite (i.e. Rocaltrol, alphacalcidiol), PTH treatment 
(i.e. Teriparatide), or Calcitonin at baseline and unwillingness to forego these treatments 
during the course of the trial  
5. Current or recent (previous 4 months) participation in another clinical trial, or plans of 
such participation in the next 3 years (corresponding to DO-HEALTH length)  
6. Presence of the following diagnosed health conditions in the last 5 years: history of 
cancer (except non-melanoma skin cancer); myocardial infarction, stroke, transient 
ischemic attack, angina pectoris, or coronary artery intervention  
7. Severe renal impairment (creatinine clearance ≤15 ml/min) or dialysis, hypercalcaemia  
(>  2.6 mmol/l)  
8. Hemiplegia or other severe gait impairment  
9. History of hypo- or primary hyperparathyroidism  
10. Severe liver disease  
11. History of granulomatous diseases (i.e. tuberculosis, sarcoidosis)  
12. Major visual or hearing impairment or other serious illness that would preclude 
participation  
13. Living with a partner who is enrolled in DO-HEALTH (i.e. only one person per household 
can be enrolled)  
14. Living in assisted living situations or a nursing home  
15. Temporary exclusion: acute fracture in the last 6 weeks  
16. Epilepsy and/or use of anti-epileptic drugs  
17. Individuals who fell more than 3 times in the last month  
18. Osteodystrophia deformans (M. Paget, Paget's disease)  
19. For study center in Germany only: persons who were institutionalized / in prison by 
court order (§40, Abs. 1, Art. 4, “Gesetz über den Verkehr mit Arzneimitteln”) 
Legend: MMSE: Mini Mental State Examination; PTH: Parathyroid hormone.  
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randomization center. The producer of the study capsules (DSM 
Nutritional Products Ltd., Switzerland) sent the study capsule bottles, 
each one containing the monthly capsule supply, to the randomization 
center, which packaged the capsules together into kits of 12 bottles 
each (a one-year supply for one participant), labeling each bottle and 
the kit's box itself with a unique randomization code. Similarly, the 
exercise kits (video plus matching paper version) were labeled by the 
randomization center with another unique randomization code. The 
web-based randomization service, developed and supported by the DO- 
HEALTH software partner (FDS), stored the information linking the 
randomization codes to the actual content of the study capsule kits and 
exercise kits. No cases of unblinding was necessary, therefore there was 
no access to this code until the data set was frozen and the study was 
unblinded. 
Kits of study capsules and exercise kits were sent to the recruitment 
centers with the individual coding. Externally, study capsule kits (vi-
tamin D alone, n-3 s alone, combination, placebo) and exercise kits 
(strength or flexibility) were identical in appearance, except for the 
randomization code on the labels. All study staff members at each trial 
site were blinded to treatments, with the exception of the “instruction 
physiotherapist” who instructed the program at baseline (unblinding 
only with respect to the type of exercise) and was not part of the DO- 
HEALTH staff team. Thus, study interventions were double-blinded in 
DO-HEALTH, including the exercise program as participants were told 
that they would get one of two exercises. 
2.15.2. Blood samples 
The laboratory analyses and biobank storage were coordinated by 
the DO-HEALTH Data Management Team with restricted access to re-
sults to avoid potential un-blinding via laboratory results. The handling 
and labeling of all samples were anonymous and standardized, and 
implemented by the coordinating team of DO-HEALTH at the co-
ordinating site in Zurich. 
2.16. Adherence assessment 
2.16.1. Study capsules adherence 
Adherence to study intervention was assessed by blood levels of 
25(OH)D and polyunsaturated fatty acids (PUFA) in all participants at 
12, 24, and 36 months. DSM Analytical Research Center performed 
25(OH)D serum measurements with gold standard HPLCMS/MS 
methodology, and PUFA measurements by a sensitive and selective 
assay based on gas chromatography coupled to mass spectrometry de-
tection (GC–MS). DSM Analytical Research Center is accredited ac-
cording to ISO 9001:2008. 
Adherence was also monitored at each contact (3-monthly phone 
calls and clinical visits at 12, 24, and 36 months) by participant self- 
report, at the same time investigating the reasons why or why not 
participants adhered to the study intervention and/or any difficulties 
encountered in following the intervention regimen. Finally, participants 
were asked to bring all used, partially used, and full bottles of study 
capsules to the clinical visits at 12, 24, and 36 months for pill counts. 
2.16.2. Study exercises adherence 
Adherence to the exercise program was monitored at each contact 
(3-montly phone calls and clinical visits at 12, 24, and 36 months), by 
participant self-report. We also investigated the reasons why or why not 
participants adhered to the exercise program and/or any difficulties 
encountered in following the program without asking about which 
exercise program was being used by the participant. If any of the ex-
ercises caused problems, the assessment staff asked the “instruction 
physiotherapist”, who was unblinded to the type of exercise, to contact 
the participant. Adherence was supported by motivational strategies at 
each contact (every 3 months). 
2.16.3. Safety monitoring 
At each clinical visit, safety markers (calcium and creatinine 
clearance) were analyzed by express tests performed at the laboratories 
of each trial site. Overall, the adverse events with vitamin D and n-3 s 
were expected to be rare [25,37,63,86]. Also, the home exercise pro-
gram was well tolerated in the pilot trial among hip fracture patients, 
and adverse events were also expected to be rare [63]. 
2.16.4. Adverse events definition 
Participants were questioned about adverse events (AEs) at each 
study visit and at each 3-monthly phone contact. AEs or abnormal test 
findings potentially associated with the study treatment(s) were fol-
lowed until the event (or its sequelae) or the abnormal test finding 
resolved or stabilized. 
For each AE, the investigator was provided with the onset, duration, 
intensity, treatment required, outcome and action taken with the in-
vestigational product. 
The intensity of AEs was assessed as being: mild (hardly noticeable, 
negligible impairment of well-being), moderate (marked discomfort, 
but tolerable without immediate relief), or severe (overwhelming dis-
comfort, calling for immediate relief). 
2.16.5. Serious adverse events definition 
Serious adverse event (SAEs) were defined as any untoward medical 
occurrence that at any dose: resulted in death; was life-threatening; 
required subject hospitalization or prolongation of current hospitali-
zation; resulted in persistent or significant disability/incapacity; or any 
important medical event and any event which, though not included in 
the above, may jeopardise the subject or may require intervention to 
prevent one of the outcomes listed above. All SAEs were reported to the 
sponsor of the trial. The Data Safety and Monitoring Board (DSMB) 
consisted of 3 independent experts and without any other relationship 
to the DO-HEALTH study, no financial interest in the outcome of the 
study, and was excluded from authorship of study findings. The DSMB 
examined the progress and safety data of the DO-HEALTH trial and 
produced an annual statement to recommend continuation of the trial. 
2.16.6. Analysis plan and statistical power 
All analyses plans were pre-defined and reviewed by the PI, the DO- 
HEALTH epidemiology team, and the head biostatistician. No interim 
analysis was planned, and none was requested by the Data Safety and 
Monitoring Board. All necessary programs for the analyses and for the 
preparation of datasets were coded in the SAS statistical language and 
stored as electronic SAS files in the designated storage folders. 
The epidemiology team at the DO-HEALTH coordinating center will 
conduct all statistical analyses using SAS v9.4 statistical software 
(Copyright© 2004 by SAS Institute Inc., Cary, NC, USA). To account for 
multiple comparisons, the significance threshold will be set at p  <  .01 
for the primary outcomes. In analyses for all other endpoints, a p-value 
of 0.05 (two-sided) will be considered a threshold for statistical sig-
nificance. 
2.16.7. Analysis of treatment effects 
In this 2 × 2 × 2 factorial design, the primary aim is to compare the 
main effects and the combined effects of vitamin D, n-3 s, and the SHEP 
on the 6 primary endpoints. All analyses will be performed based on 
intent-to-treat, so that all available data will be included for all study 
participants. 
Our general approach is to use longitudinal linear regression models 
for continuous outcomes (systolic and diastolic blood pressure and 
MoCa), with changes from baseline at 1, 2, and 3 years as outcomes, 
adjusting for correlation between serial measurements from the same 
patient. For the non-normally distributed outcomes (SPPB), Generalized 
Estimating Equations (GEE) with an unstructured correlation matrix 
will be used to account for correlation within participants over time. 
These models will include fixed effects for the interventions, as well as 
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adjust for the stratification variables (study center, age, sex, prior fall), 
the appropriate baseline outcome measure, time as a categorical pre-
dictor, intervention by time interaction effects (if significant), and 
baseline BMI as a pre-defined potential confounder. For non-vertebral 
fractures and infections, we will use the analogous Poisson regression 
model with each participant’s time in the study as an exposure offset. 
First, these models will be used to determine for each outcome 
whether the intervention effects are additive. In addition to the main 
intervention effects and the predictors described above, we will include 
two- and three-way interaction terms between interventions. For out-
comes for which interactions are found, all subsequent models will treat 
the study as an 8-armed trial with indicator variables for the 8 inter-
vention combinations. For outcomes for which interactions are not 
significant, all subsequent models will include only the main effect of 
each intervention (plus adjustment covariates); combined effects of the 
interventions will be estimated by adding the individual effects. 
Second, these models will be used to determine the longitudinal effects 
of the interventions across all 3 years of follow-up. For outcomes with no 
treatment interactions, the group of patients who received an intervention is 
compared to the group who did not. For outcomes with treatment inter-
actions, the arm that received a particular intervention along with no other 
interventions was compared to the arm that received none of the three 
interventions. For each outcome, the initial model will include indicators for 
the intervention groups, indicators for time, and interactions between in-
terventions and time to assess whether there are progressive benefits due to 
intervention over time (adjustments for covariates and correlation remain as 
described above). If interaction terms are found to be non-significant, they 
will be removed, leaving the main effect of each intervention to represent 
the consistent, average impact of the intervention across all three years. See 
Appendix 2 for model equations. 
2.16.8. Power 
The planned sample size for this study was N = 2152 older adults 
(Table 2). Based on prior experience and results of pilot studies the dropout 
rate was estimated at 32%, while 68% of participants were expected to 
complete the entire 36-month follow-up. Since the trial analysis is based on 
the intention-to-treat principle, partial study data would be available from 
the 32% of subjects who are expected to drop out early. Therefore, the 
estimated effective sample size for the analysis was 1807 people: full follow- 
up data on 68% of the 2152 enrolled older adults (0.68 × 2152 = 1463), 
plus an average of half follow-up on the 689 of subjects who were expected 
to withdraw early (0.5 × 0.32 × 2152 = 344). 
2.17. Missing data 
Handling of missing data for the 6 primary outcomes depends on the 
amount of data being missing. If < 1% of data are missing, it will be 
considered as missing completely at random (MCAR)and we will per-
form complete-case analysis, which yields unbiased parameter esti-
mates albeit with reduced statistical power. 
For continuous primary outcomes (function; blood pressure; and 
cognition), if > 1% of data are missing, analysis will be performed 
using models assuming data are missing at random such as the mixed 
effects model. Sensitivity analysis will also be performed using multiple 
imputation, which is implemented in SAS via the ‘PROC MI’ and ‘PROC 
MIANALYZE’ procedures. 
For binary (non-vertebral fractures) and ordinal (number of infec-
tions) outcomes, statistical analysis models will adjust for time-in-study 
and no imputation will be performed. 
Handling of missing data for secondary outcomes follow the same 
procedure described above for the primary outcomes. 
2.18. Ethics 
DO-HEALTH was approved by local/national ethics committee and 
regulatory authorities of all 5 countries (Switzerland, Germany, Austria, 
France, Portugal). DO-HEALTH was a Phase III trial (therapeutic con-
firmatory) and was conducted according to the ICH GCP Guidelines 
(CPMP/ICH/135/95). 
2.19. Trial registration and funding 
DO-HEALTH is registered under the protocol NCT01745263 at the 
International Trials Registry (clinicaltrials.gov), and under the protocol 
number 2012–001249-41 at the Registration at the European 
Community Clinical Trial System (EudraCT). 
DO-HEALTH was funded by the European Commission Framework 
7 Research Program (project number 278588), the University of Zurich 
(Chair of Geriatrics and Aging Research), and independent, investigator 
initiated funds provided by DSM Nutritional Products, ROCHE 
Diagnostics (SCHWEIZ), NESTEC, Pfizer Consumer Healthcare, and 
STREULI Pharma. The funders had no role in the DO-HEALTH study 
design or writing of the report. 
3. Discussion 
DO-HEALTH is the largest European healthy aging trial including 5 
European countries. The goal of the DO-HEALTH trial was to address 6 
primary endpoints (systolic and diastolic blood pressure, non-vertebral 
fractures, SPPB [34], MoCA [35], and infections) relevant to healthy aging 
among community-dwelling adults age 70 years and older. In this frame-
work, DO-HEALTH was designed, through intensive monitoring of 2152 
participants every 3 months, to address changes in important risk factors, 
such as functional/cognitive decline and elevated blood pressure, rather than 
major clinical events such as dementia, myocardial infarction or stroke. The 
3 interventions tested in DO-HEALTH: n-3 s, vitamin D, a simple home 
strength exercise, were selected to be well-tolerated and affordable, allowing, 
if proven effective, to be implemented at a large-scale public health level. 
DO-HEALTH has several strengths. It targets the relatively healthy 70+ 
age segment of the population expected to grow rapidly in the coming 
years, at an age where disease rates are increasing exponentially. Further, as 
a healthy aging trial, it is powered for 6 primary endpoints from 5 health 
domains: systolic and diastolic blood pressure changes (cardiovascular), 
incidence of non-vertebral fractures (bone), functional decline (muscle), 
cognitive decline (brain), and rate of infection (immunity). Additionally, a 
series of pre-defined and well-integrated secondary endpoints and ancillary 
studies were designed to explore the role of the interventions also with 
regard to joint, mental, dental, gastro-intestinal, glucose-metabolic, kidney 
and global health. Its detailed follow-up including yearly whole-day clinical 
visits and 3-monthly phone calls in all participants includes the assessment 
of key life-style factors such as nutrition, education, and physical activity, as 
well as comorbidities and the use of prescription drugs and over the counter 
supplements. The factorial design (2×2×2) was chosen to identify the role 
of the individual and combined effects of the 3 interventions. Blood col-
lection and analysis of 25(OH) D and PUFAs (EPA + DHA), were assessed in 
all participants at baseline, 12, 24, and 36 month follow-up and thereby 
provide an excellent measure of adherence to the study medication. Further, 
the extensive 55-item DO-HEALTH biomarker study (Supplementary 
Table 1), assessed in all participants at all time points, support the DO- 
HEALTH clinical endpoints at the mechanistic level and will help extend our 
understanding of the effect of the interventions in relation to many well- 
integrated additional secondary and tertiary endpoints to be explored in 
pre-defined ancillary studies. 
Finally, because DO-HEALTH was a multicenter study with detailed 
and standardized phenotyping of all participants, health disparities 
between the 5 European countries will be also explored, as will the 
genetic profiles depending on further funding availability for the bio-
bank of DO-HEALTH. 
Our trial also has limitations. Only one dose of vitamin D and n-3 s 
was tested. However, the dose for each agent was chosen based on an 
extensive review of available evidence, including several pilot studies 
[37,63] and meta-analyses [25,93,94]. Further, serum baseline and 
H.A. Bischoff-Ferrari, et al.   Contemporary Clinical Trials 100 (2021) 106124
10
achieved concentration of the related biomarkers 25(OH)D and 
EPA + DHA will be analyzed to test changes in the endpoints addressed 
in DO-HEALTH by changes in the biomarkers. Another limitation may 
be that in order to have a placebo group in DO-HEALTH, we allow all 
participants to take 800 IU vitamin D per day according to current 
guidelines. This may bias our findings for vitamin D towards a con-
servative comparison between the tested higher dose of 2000 IU to 
800 IU. Finally, our findings may not be applicable to younger adults, or 
less healthy community-dwelling adults age 70 years, or older or in-
stitutionalized older adults. 
Given the broad popularity of supplement use of vitamin D and n- 
3 s, the clarification of their role in supporting several endpoints among 
the growing segment of older adults is of enormous public health re-
levance. For vitamin D, the evidence for the prevention of falls and 
fractures, especially among healthy older adults without osteoporosis 
and vitamin D deficiency have been broadly discussed [6,95–98] and 
needs further clarification from a large clinical trial. 
Marine n-3 s have shown considerable promise for the secondary 
prevention of cardiovascular disease in high-risk settings [99–101]. 
Few studies, however, addressed the long-term use of n-3 s in primary 
prevention of cardiovascular-health. Further, current data from clinical 
trials are limited and inconsistent regarding the role of n-3 s with regard 
to bone, muscle, brain, and immunity [102–109]. DO-HEALTH will 
advance the state of the science by comparing the long-term effect of n- 
3 s against placebo and combined with vitamin D and/or exercise. 
Physical exercise has shown considerable promise as a compre-
hensive prevention strategy for many age-related diseases, such as os-
teoporosis [110], and fall prevention [111–115], as well as cardio- 
vascular health [32,116–118]. However, data on fracture reduction are 
lacking from randomized controlled trials, and the role of a well-de-
fined simple home exercise program with regard to several endpoints 
relevant to aging, as tested in DO-HEALTH, needs further clarification. 
In conclusion, we expect that DO-HEALTH findings will have a large 
impact on public health as the interventions can be easily implemented 
in clinical practice, and the endpoints are relevant to the overall health 
of older adults because they address several health domains including 
cardiovascular, muscle, bone, brain and immunity. 
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